Company Description

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder.

The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.

Definium Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Definium Therapeutics, Inc.

Country	United States
Founded	2019
Industry	Biotechnology
Sector	Healthcare
Employees	74
CEO	Robert Barrow

Contact Details

Address: One World Trade Center, Suite 8500 New York, New York 10007 United States
Phone	212 220 6633
Website	definiumtx.com

Stock Details

Ticker Symbol	DFTX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001813814
CUSIP Number	24477V105
ISIN Number	CA24477V1058

Key Executives

Name	Position
Robert Barrow	Chief Executive Officer and Director
Mark R. Sullivan J.D.	Chief Legal Officer and Corporate Secretary
Dr. Daniel Rollings Karlin M.A., M.D.	Chief Medical Officer
Dr. Scott M. Freeman M.D.	Co-Founder and Clinical Advisor
Leonard Latchman	Co-Founder
Brandi L. Roberts CPA, M.B.A.	Chief Financial Officer
Peter Mack	Senior Vice President of Pharmaceutical Development and Operations
Gitanjali Jain Ogawa	Vice President and Head of Investor Relations
Beth Calitri	Vice President of Corporate Communications
Stephanie Fagan	Chief Corporate Affairs Officer